Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 7, 2011 - Issue 3
Submit an article Journal homepage
229
Views
21
CrossRef citations to date
0
Altmetric
Drug Profile

Leflunomide in renal transplantation

W James Chon Section of Nephrology, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, MC 5100, Chicago, IL 60637, USA; Section of Nephrology, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, MC 5100, Chicago, IL 60637, USA
&
Michelle A Josephson Section of Nephrology, Department of Medicine, University of Chicago, 5841 South Maryland Avenue, MC 5100, Chicago, IL 60637, USA;[email protected]
Pages 273-281 | Published online: 10 Jan 2014

References

  • Cameron JI, Whiteside C, Katz J, Devins GM. Differences in quality of life across renal replacement therapies. A meta-analytic comparison. Am. J. Kidney Dis.35, 629–637 (2000).
  • Jofre R, Lopez-Gomez JM, Moreno F, Sanz-Guajardo D, Valderrabano F. Changes in quality of life after renal transplantation. Am. J. Kidney Dis.32, 93–100 (1998).
  • Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med.341, 1725–1730 (1999).
  • Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med.342, 605–612 (2000).
  • Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N. Engl. J. Med.346, 580–590 (2002).
  • Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival. Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am. J. Transplant.4, 1289–1295 (2004).
  • Meier-Kriesche HU, Schold JD, Srnivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant.4, 378–383 (2004).
  • Husky J, Gralla J, Wiseman AC. Single time point immune function assay (ImmuKnow™) testing does not aid in the prediction of future opportunistic infections or acute rejection. Clin. J. Am. Soc. Nephrol. DOI: 10.2215/CJN.04210510 (2010) (Epub ahead of print).
  • Schena F, Pascoe M, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24 months efficacy and safety results from the CONVERT trial. Transplantation87, 233 (2009).
  • Pearson TC, Mulgaonkar S, Patel A et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitors (CNI) withdrawal in renal transplant recipients: final results of the Spare-the-Nephron (STN) trial. Am. J. Transplant.8(S2), 213 (2008) (Abstract 129).
  • Servais A, Meas-Yedid V, Lebranchu Y et al. Comparison at one year of interstitital fibrosis (IF) by automatic quantification in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction. Am. J. Transplant.8(S2), 159 (2008) (Abstract 527).
  • Vincenti F, Charpertier B, Vanrenterghem Y et al. A Phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study). Am. J. Transplant.10, 535–546 (2010).
  • Durrbach A, Pestana JM, Pearson T et al. A Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study). Am. J. Transplant.10, 547–557 (2010).
  • Ausustine JJ, Hricik DE. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes and remaining questions. Clin. J. Am. Soc. Nephrol.1, 1080–1089 (2006).
  • Williams JW, Javaid B, Kadambi PV et al. Leflunomide for polyomavirus type BK nephropathy. N. Engl. J. Med.352, 1157–1158 (2005).
  • Josephson MA, Gillen D, Javaid B et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation81, 704–710 (2006).
  • Teschner S, Gerke P, Geyer M et al. Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection. Transplant. Proc.41, 2533–2538 (2009).
  • Leca N, Muczynski KA, Jefferson JA et al. Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for virus clearance in renal transplant patients. Clin. J. Am. Soc. Nephrol.3, 829–835 (2008).
  • Faguer S, Hirsch HH, Kamar N et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transplant. Int.20, 962–969 (2007).
  • Basse G, Mengelle C, Kamar N et al. Prospective evaluation of BK virus DNAemia in renal transplant patients and their transplant outcome. Transplant. Proc.39, 84–87 (2007).
  • Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative HWA486, with potential antirheumatic activity-I. Disease modifying action on adjuvant arthritis of the rat. Int. J. Immunopharmacol.7, 7–18 (1985).
  • Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trail. Lancet353, 259–266 (1999).
  • Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Arch. Intern. Med.159, 2542–2550 (1999).
  • Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology39, 655–665 (2000).
  • Weinblatt ME, Jremer JM, Coblyn JS et al. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum.42, 1322–1328 (1999).
  • Osiri M, Shea B, Robinson V et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J. Rheumatol.30, 1182–1190 (2003).
  • Rozman B. Clinical pharmacokinetics of leflunomide. Clin. Pharmacokinet.41, 421–430 (2002).
  • Leflunomide®, package insert. Aventis Pharmaceuticals Inc., Kansas City, NJ, USA.
  • Williams JW, Mital D, Chong A et al. Experiences with leflunomide in solid organ transplantation. Transplantation73, 358–366 (2002).
  • Chong AS, Huang W, Liu W et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation68, 100–109 (1999).
  • Elder RT, Xu X, Williams JW, Gong H, Finnegan A, Chong AS. The immunosuppressive metabolite of leflunomide, A771726, affects murine T cells through two biochemical mechanisms. J. Immunol.159, 22–27 (1997).
  • Siemasko K, Chong AS, Jack H, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by immunosuppressive drug leflunomide leads to a block in IgG1 production. J. Immunol.160, 1581–1588 (1998).
  • Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem.270, 12398–12403 (1995).
  • McChesney LP, Xiao F, Sankary HN et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation57, 1717–1722 (1994).
  • Kuchle CCA, Thoenes GH, Langer KH et al. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant. Proc.23, 1083–1086 (1991).
  • Williams JW, Xiao F, Foster P et al. Leflunomide in experimental transplantation. Transplantation57, 1223–1231 (1994).
  • Xiao F, Chong A, Shen J et al. Pharmacologically induced regression of chronic transplant rejection. Transplantation60, 1065–1072 (1995).
  • Lin Y, Waer M. In vivo mechanism of action of leflunomide: selective inhibition of the capacity of B lymphocytes to make T-independent xenoantibodies. Transplant. Proc.28, 3085 (1996).
  • Xiao F, Shen J, Chong A et al. Control and reversal of chronic xenograft rejection in hamster-to-rat cardiac transplantation. Transplant. Proc.29, 691–692 (1996).
  • Williams JW, Xiao F, Foster P, Kociss K, Chong A, Sankary H. Leflunomide and cyclosporine A in rat cardiac transplantation. Transplant. Proc.25, 74 (1993).
  • Sankary HN, Yin D, Chong AS et al. FK 506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. Transplantation66, 832–837 (1998).
  • Farasati NA, Shapiro R, Vats A et al. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation79, 116–118 (2005).
  • Liacini A, Seamone ME, Muruve DA, Tibbles LA. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation90, 1450–1457 (2010).
  • Bernhoff E, Tylden GD, Kjerpeseth LJ, Gutteberg TJ, Hirsch HH, Rinaldo CH. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J. Virol.84, 2150–2156 (2010).
  • Waldman WJ, Knight DA, Lurain NS et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation68, 814–825 (1999).
  • Waldman WJ, Knight DA, Blinder L et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology42, 412–418 (1999).
  • John GT, Manivannan J, Chandy S, Peter S, Jacob CK. Leflunomide therapy for cytomegalovirus disease in renal allograft recipients. Transplantation77, 1460–1461 (2004).
  • Levi ME, Maandava N, Chan LK, Weinberg A, Olson JL. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl. Infect. Dis.8, 38–43 (2006).
  • Avery RK. Utility of leflunomide in the treatment of complex cytomegalovirus syndrome. Transplantation90, 419–426 (2010).
  • Chong AS, Zeng H, Knight DA et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am. J. Transplant.6(1), 69–75 (2006).
  • Davis JP, Cain GA, Pitts WJ et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry35, 1270–1273 (1996).
  • Knecht W, Loffler M. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Biochem. Pharmacol.56, 1259–1264 (1998).
  • Williamson RA, Yea CM, Robinson PA et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A771726 and mediator of a range of biological effects of immunomodulatory compound. J. Biol. Chem.270, 22467–22472 (1995).
  • Cherwinski HM, Byars N, Ballaron SJ et al. Leflunomide interferes with pyrimidine nucleotide biosynthsis. Inflamm. Res.44, 317–322 (1995).
  • Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett.334, 161–164 (1993).
  • Shawver LK, Schwartz DP, Mann E et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin. Cancer Res.3, 1167–1177 (1997).
  • Xu X, Shen J, Mall JW et al.In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action. Biochem. Pharmacol.58, 1405–1413 (1999).
  • Sawamukai N, Saito K, Yamaoka K, Nakayamada S, Ra C, Tanaka Y. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells. J. Immunol.179, 6479–6484 (2007).
  • Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-κB, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J. Immunol.165, 5962–5969 (2000).
  • Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A771726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J. Immunol.162, 2095–2102 (1999).
  • Xiao F, Chong AS, Foster P et al. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation58, 828–834 (1994).
  • Leca N. Leflunomide use in renal transplantation. Curr. Opin. Organ Transplant.14, 370–374 (2009).
  • Araya CE, Garin EH, Neiberger RE, Dharnidharka VR. Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients. Pediatr. Transplantation14, 145–150 (2010).
  • Knight DA, Hejmanowski AQ, Dierksheide JE et al. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation71, 170–174 (2001).
  • Hardinger KL, Wang CD, Schnitzler MA et al. Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am. J. Transplant.2, 867–871 (2002).
  • Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation87, 1019–1026 (2009).
  • Smith JM, Dharnidharka VR, Talley L, Martz K, McDonald RA. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin. J. Am. Soc. Nephrol.2, 1037–1042 (2007).
  • Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation79, 1277–1286 (2005).
  • Nickeleit V, Mihatsch MJ. Polyomavirus nephropathy in native kidneys and renal allografts: an update on an escalating threat. Transpl. Int.19, 960–973 (2006).
  • Dropulic LK, Jones RJ. Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplantation41, 11–18 (2008).
  • Lekakis L, Macrinici V, Baraboutis IG, Mitchell B, Howard DS. BK virus nephropathy after allogeneic stem cell transplantation: a case report and literature review. Am. J. Hematol.84, 243–246 (2009).
  • Haririan A, Ramos ER, Drachenberg CB, Weir MR, Klassen DK. Polyomavirus nephropathy in native kidneys of a solitary pancreas transplant recipient. Transplantation73, 1350–1353 (2002).
  • Egli A, Helmersen DS, Taub K, Hirsch HH, Johnson A. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. Am. J. Transplant.10, 2324–2330 (2010).
  • Egli A, Kohli S, Dickenmann M, Hirsch HH. Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs. Transplantation88, 1161–1168 (2009).
  • Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation87, 621–630 (2009).
  • Bonvoism C, Weekers L, Xhignesse P et al. Polyomavirus in renal transplantation: a hot problem. Transplantation85, S42–S48 (2008).
  • Koukoulaki M, Grispou E, Pistolas D et al. Prospective monitoring of BK virus replication in renal transplant recipients. Transpl. Infect. Dis.11, 1–10 (2008).
  • Bressollette-Bodin C, Coste-Burel M, Hourmant M, Sebille V, Andre-Garnier E, Imbert-Marcille BM. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am. J. Transplant.5, 1926–1933 (2005).
  • Hirsch HH, Randhawa P. AST Infectious Diseases Community of Practice. BK virus in solid organ transplant recipients. Am. J. Transplant.9, S136–S146 (2009).
  • Brennan DC, Agha I, Bohl DL et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am. J. Transplant.5, 582–594 (2005).
  • Weiss AS, Gralla J, Chan L, Klem P, Wiseman AC. Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies. Clin. J. Am. Soc. Nephrol.3, 1812–1819 (2008).
  • Saad ER, Bresnahan BA, Cohen EP et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation85, 850–854 (2008).
  • Ramos E, Drachenberg CB, Portocarrero M et al. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin. Transpl.2002, 143–153 (2002).
  • Ramos E, Drachenberg CB, Papadimitriou JC et al. Clinical course of polyoma virus nephropathy in 67 renal transplant recipients. J. Am. Soc. Nephrol.13, 2145–2151 (2002).
  • Rinaldo CH, Hirsch HH. Antivirals for the treatment of polyomavirus BK replication. Expert Rev. Anti Infect. Ther.5, 105–115 (2007).
  • Kuypers DR, Vandooren AK, Lerut E et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitital nephritis in renal transplant recipients. Am. J. Transplant.5, 1997–2004 (2005).
  • Kadambi PV, Josephson MA, Williams J et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am. J. Transplant.3, 186–191 (2003).
  • Scantlebury V, Shapiro R, Randhawa P et al. Cidofovir: a method of treatment for BK virus-associated transplant nephropathy. Graft60, 125 (2002).
  • Sener A, House AA, Jevnikar AM et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation81, 117–120 (2006).
  • Randhawa PS. Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin. Infect. Dis.41, 1366–1367 (2005).
  • Leung AYH, Chan MTL, Yuen K et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis.40, 528–537 (2005).
  • Gabardi S, Waikar SS, Martin S et al. Evaluation of flouroquinolones for the prevention of BK viremia after renal transplantation. Clin. J. Am. Soc. Nephrol.5, 1298–1304 (2010).
  • Josephson MA, Javaid B, Kadambi PV, Meehan SM, Williams JW. Leflunomide in solid organ transplantation and polyoma virus infection. Adv. Exp. Med. Biol.577, 255–265 (2006).
  • Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation89, 1057–1070 (2010).
  • Wadei HM, Rule AD, Lewin M et al. Kidney transplant function and histological clearance of virus following the diagnosis of polyomavirus-associated nephropathy. Am. J. Transplant.6, 1025–1032 (2006).
  • Randhawa P, Ramos E. BK viral nephropathy: an overview. Transplantation Reviews21, 77–85 (2007).
  • Swan SK, Crary GS, Guijarro C et al. Immunosuppressive effects of leflunomide in experimental chronic vascular rejection. Transplantation60, 887–890 (1995).
  • Briffa NP, Shorthouse R, Chan J et al. Histological and immunological characteristics of the effect of immune suppressive treatment on xenograft vasculopathy. Xenotransplantation11, 149–159 (2004).
  • Carulli MT, Davies UM. Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology41, 952–953 (2002).
  • Kho LK, Kermode AG. Leflunomide-induced peripheral neuropathy. J. Clin. Neurosci.14, 179–181 (2007).
  • Metzler C, Arlt AC, Gross WL, Brandt J. Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide. Ann. Rheum. Dis.64, 1798–1800 (2005).
  • Martin K, Bentaberry F, Dumoulin C et al. Neuropathy associated with leflunomide: a case series. Ann. Rheum. Dis.64, 649–650 (2005).
  • Richards BL, Spies J, McGill N et al. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Int. Med. J.37, 101–107 (2007).
  • Vanrenterghem Y, van Hooff JP, Klinger M et al. The effects of FK778 in combination with tacrolimus and steroids: a Phase II multicenter study in renal transplant patients. Transplantation78, 9–14 (2004).
  • Zeng H, Waldman WJ, Yin DP et al. Mechanistic study of malononitrileamide FK778 in cardiac transplantation and CMV infection in rats. Transplantation79, 17–22 (2005).
  • Evers DL, Wang X, Huong SM et al. Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778. Antiviral Res.65, 1–12 (2005).
  • Guasch A, Roy-Chaudhury P, Woodle ES et al. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation90, 891–897 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.